Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: February 07, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 17.6 billion |
|
Revenue Forecast in 2030 |
US$ 51.21 billion |
|
CAGR |
12.6% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Type, Treatment Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global non-small cell lung cancer (NSCLC) therapeutics market was valued at US$ 17.6 billion in 2021 and is expected to register a revenue CAGR of 12.6% to reach US$ 51.21 billion by 2030.
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Fundamentals
The non-small cell lung cancer (NSCLC) therapeutics market has experienced significant revenue growth opportunities in recent years due to advancements in treatments and increase in incidence rates of NSCLC. Moreover, the market is expected to continue to grow at a significant revenue CAGR during the forecast period, driven by factors such as the approval of new treatments, increased funding for research and development activities, and the aging population.
In recent years, major cancer patient population across the globe have been increasing inclination towards personalized or precision medicine approaches, where treatments are tailored to the specific genetic makeup of an individual's cancer. This has led to the development of new targeted therapies and immunotherapies that have improved survival outcomes for patients. The increasing usage of these treatments is expected to drive market revenue growth.
However, the high cost of non-small cell lung cancer treatments and increasing competition in the market may limit the revenue growth of the market. Additionally, reimbursement and regulatory policies and the time and resources required to bring new treatments to market are significant challenges for the industry.
Non-small cell lung cancer is the most common type of lung cancer, accounting for about 85% to 90% of all cases. Non-small cell lung cancer refers to a group of lung cancers characterized by their rapid growth and spread to other parts of the body, but do not exhibit the same patterns of growth and spread as small cell lung cancer.
Non-small cell lung cancer can be further classified into subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, based on the appearance of cancer cells under a microscope. The adenocarcinoma type of lung cancer develops in cells that release mucus and other chemicals. It typically starts in the lung’s outermost regions. Squamous cell carcinoma typically develops in the center of the lungs, which begins with squamous cells, the flat cells that line the interior of the airways. Moreover, there are other types of non-small cell lung cancer, including sarcomatoid carcinoma, adenosquamous carcinoma, salivary gland carcinoma, carcinoid tumor, and unclassified carcinoma. The non-small cell lung cancer is categorized into five stages, from stage 0 to stage 4.
Non-small cell lung cancer diagnosis and staging tests and procedures are frequently carried out concurrently. There are different types of diagnostic procedures, such as physical examination, laboratory tests, CT scans, chest X-rays, sputum cytology, and thoracentesis. Current non-small cell lung cancer treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, laser therapy, photodynamic therapy (PDT), cryosurgery, and electrocautery. Immune checkpoint inhibitors (ICIs) have become a key standard of care for treating patients with advanced non-small cell lung cancer, whether in the first line of treatment or beyond, over the past several years.
[8657575]
Non-small Cell Lung Cancer (NSCLC) Therapeutics Market Dynamics
The non-small cell lung cancer accounts for around 85% to 90% of cases of lung cancer globally, which plays a significant role in the revenue growth of the non-small cell lung cancer therapeutics market. The rise in the prevalence of non-small cell lung cancer around the world due to increasing air pollution and soaring cigarette consumption is boosting revenue growth of the non-small cell lung cancer non-small cell lung cancer therapeutics market.
The growing geriatric population is increasing the patient pool for non-small cell lung cancer. According to the American Cancer Society, many lung cancer patients are of age 65 or older. The rise in R&D activities to develop innovative therapies, such as immunotherapy, targeted therapy, and hormone therapies, is boosting the demand for non-small cell lung cancer treatment. Moreover, the increased development of innovative medications, such as inhibitors and biologics, with a broad drug pipeline is also an important factor in fueling revenue growth in the non-small cell lung cancer therapeutics market. Moreover, the demand for non-small cell lung cancer treatment is also rising as the government and non-government organizations globally are raising awareness about the importance of early cancer diagnosis and treatment.
However, the market is significantly constrained by the high cost of non-small cell lung cancer therapeutic products, such as biologics, chemotherapy, and targeted therapies. Furthermore, the stringent government regulations and the high cost involved in drug development hinder revenue growth of the market.
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Ecosystem
The global non-small cell lung cancer (NSCLC) therapeutics market has been analyzed from three perspectives: type, treatment type, and region.
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Type
[9685674]
Based on type, the global non-small cell lung cancer (NSCLC) therapeutics market is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and large cell neuroendocrine tumors.
The adenocarcinoma segment accounted for the largest revenue share of the market in 2021, owing to the highest prevalence rate compared to other types. The rise in cigarette consumption is boosting segment revenue growth as the majority of persons who smoke or have smoked in the past are at higher risk of developing lung adenocarcinoma. Moreover, compared to other types of lung cancers, it is also more likely to develop at a younger age, thus increasing the demand for early diagnostics. A robust product portfolio for adenocarcinoma is also boosting the segment’s revenue growth.
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Treatment Type
Based on treatment type, the global non-small cell lung cancer (NSCLC) therapeutics market is segmented into chemotherapy, targeted drug therapy, and immunotherapy.
The chemotherapy segment dominated the non-small cell lung cancer (NSCLC) therapeutics market in 2021. Chemotherapy is regarded as the first line of treatment for the majority of cancers, thus fostering market revenue growth. Compared to other treatments, the chemotherapy technique is more cost-effective overall, contributing significantly to the revenue growth of the segment. Furthermore, chemotherapy has been utilized in conjunction with other treatments, raising demand for the drug.
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Region
Based on region, the global non-small cell lung cancer (NSCLC) therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global non-small cell lung cancer (NSCLC) therapeutics market in 2021, followed by Europe and Asia Pacific. The rising prevalence of non-small cell lung cancer in North America is the key factor for revenue growth of the global market. According to the American Society of Clinical Oncology (ASCO), around 82% of all lung cancer cases are of non-small cell lung cancer. The presence of well-developed healthcare infrastructure and growing healthcare expenditure in the region is propelling regional revenue growth. A rise in the R&D activities focused on cancer treatment and the presence of a large number of research institutes in the region are fueling regional revenue growth. The acceptance of non-small cell lung cancer therapies is anticipated to increase with the rise in lung cancer risk factors, such as the percentage of smokers in the general population and exposure to toxins, such as asbestos and air pollution. Moreover, the presence of the major players in the region is also anticipated to fuel revenue growth in the regional market.
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Competitive Landscape
The prominent players operating in the non-small cell lung cancer (NSCLC) therapeutics market are:
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Strategic Developments
The chemotherapy segment dominates the global non-small cell lung cancer (NSCLC) therapeutics market.
The global non-small cell lung cancer (NSCLC) therapeutics market is estimated to reach US$ 51.21 billion by 2030.
Bristol-Myers Squibb Company, Merck & Co Inc., Bayer AG, Novartis AG, and Sanofi S.A are among the prominent players operating in the global non-small cell lung cancer (NSCLC) therapeutics market.
The global non-small cell lung cancer (NSCLC) therapeutics market is estimated to register a revenue CAGR of 12.6% during the forecast period of 2022 to 2030.
The market for non-small cell lung cancer (NSCLC) treatments is characterized by an increase in biologic innovations as well as research and development activities in the NSCLC field.
*Insights on financial performance are subject to the availability of information in the public domain